CD8A and cancer: In pursuit of a comprehensive neoantigen prediction model grounded in a tumor-reactive TIL TCR-pMHC ternary complex, we conducted scRNA-seq on a collective pool of 202,575 CD8+ TILs obtained from the training cohort of 25 cancer patients for neoantigen prediction workflows (CRC: 6, GC: 11, HCC: 6, MN: 2) (Supplementary Fig. 3a).